Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …

Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by
autoantibodies directed against self red blood cells. It can be idiopathic or secondary, and …

The terminology applied to autoimmune hemolytic anemia (AIHA) seems inconsistent. We
aimed to evaluate the consistency of definitions used for diagnosis and treatment. In this …

OBJECTIVES: Rituximab, an anti-CD20 monoclonal antibody that selectively depletes B
cells, has shown promise in autoantibody-associated, immune-mediated disorders. As …

Objective This study aims to evaluate the response to rituximab (RTX) treatment in auto-
immune hemolytic anemia (AIHA) patients. Methods Studies were selected from MEDLINE …

Summary The management of Evans Syndrome in children is challenging due to the lack of
evidence‐based data on treatment. Steroids, the first‐choice therapy, are successful in …

Abstract Objective. Rituximab (RTX), a B-cell depleting mAb, has been reported to cause
pulmonary toxicity in many patients. As the use of this biologic is increasing, we have …

There are various immune cytopenias associated with systemic lupus erythematosus (SLE).
The most common one is anemia; however, there are different etiologies for the anemia …

This prospective study investigated the efficacy, safety, and response duration of low-dose
rituximab (100 mg fixed dose for 4 weekly infusions) together with a short course of steroids …

The treatment of both auto‐immune haemolytic anaemia (AIHA) and auto‐immune
thromobocytopenic purpura (AITP) remains unsatisfactory in those refractory to first‐line …